Ramondetta LM, et al. - In this investigation, researchers identified throughout primary treatment the feasibility of pharmacologic beta-adrenergic blockade in women with newly diagnosed stage II-IV epithelial ovarian cancer (EOC). Prior to beginning chemotherapy or surgery, patients initiated propranolol. Participants in the study were 26 patients. Findings revealed that the use of propranolol during primary EOC treatment is feasible and treatment has resulted in a decrease in adrenergic stress response markers. Propranolol potentially results in improved quality of life over baseline in combination with chemotherapy.